SGMT - Sagimet Biosciences, Inc. Profit before interest, taxes and amortization

Brandmark of Sagimet Biosciences Inc. (SGMT)

Sagimet Biosciences (SGMT) is striving for pricing power through its innovative liver fibrosis drug. The EBITDA_Co trend reflects a model adaptation, with the current level sitting around 0.00. High scalability is ensured by patents on affordable formulas. Business stability is supported by a strong team of biochemists attracted by stock options and ambitious clinical trials in the field of metabolism.

Sagimet - SGMT Operating profit EBITDA (period 11/23/2025 - 11/16/2026)

Summary analytical data breakdowns for sagimet.com (SGMT)

- current quotes and average value forecast:
Analysis of all company metrics:Sagimet Biosciences (SGMT)
Manufactured products of Sagimet Biosciences

Investors are assessing the resilience of Sagimet Biosciences (SGMT) through operational efficiency, where this indicator measures earnings before interest, taxes, depreciation, and amortization, reflecting the actual cash flow from core operations. By analyzing the company's aggregate EBITDA, one can identify anomalies in the development costs for NASH drugs, which, unlike market cycles, depend exclusively on clinical results and strategic partnerships.

Who Sagimet Biosciences competes with

ASND - Operating profit before deduction of amortization|Madrigal Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Corcept|RYTM (Rhythm Pharmaceuticals, Inc.) - Operating profit before deduction of amortization|AKRO: Company profit before taxes, interest and amortization|MTSR (Metsera Therapeutics) - Operating profit EBITDA|Operating profit EBITDA MoonLake Immunotherapeutics|Operating profit EBITDA CRNX|Profit before payment of interest, taxes and amortization NAMS (NewAmsterdam Pharma Company)|Profit before payment of interest, taxes and amortization soleno.life SLNO|Amicus Corp (FOLD) - Profit before interest, taxes and amortization|ETNB - Profit before payment of interest, taxes and amortization|AGIO: Profit before payment of interest, taxes and amortization|GPCR: Operating profit EBITDA|MDXG - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Rezolute Bio|Lexicon Corp (LXRX) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization mbxbio.com (MBX)|Operating profit EBITDA altimmune.com (ALT)|Operating profit EBITDA AARD (aardvarktherapeutics.com)|BioAge - Profit before payment of interest, taxes and amortization|Biomea Fusion Corp - Operating profit EBITDA|QNCX - Operating profit EBITDA|GUTS: Operating profit EBITDA|VTVT (vTv Therapeutics Inc.) - Profit before payment of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Agape ATP Corp.|PLUR: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Synlogic, Inc. (SYBX)|Operating profit before deduction of amortization Lipocine Corp LPCN|Operating profit EBITDA MTNB (Matinas BioPharma Holdings, Inc.)|Spruce Biosciences (SPRB) - Profit before interest, taxes and amortization|GLTO - Profit before payment of interest, taxes and amortization|CTCX: Profit before payment of interest, taxes and amortization|LUMO: Operating profit EBITDA|Profit before interest, taxes and amortization Organovo Holdings, Inc. (ONVO)|RDUS (Radius Recycling Inc.) - Operating profit EBITDA